J07BC02 - Hepatitis A, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hepatitis A, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated hepatitis A virus.
Therapeutic characteristics
The vaccine is indicated for the active immunization of adults and children over the age of 1against hepatitis A. It is administered by a single intramuscular injection. A booster dose is recommended after 6-12 months in order to obtain more persistent immunity.
Metabolism and pharmakokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Havrix. #1876
Similar drugs
© NAPOS 2024